Sorin V. Pislaru
Mayo Clinic
Internal medicineRadiologySurgeryCardiologyHemodynamicsAortic valve replacementMitral valveHeart failureAtrial fibrillationStenosisValve replacementRegurgitation (circulation)Mitral valve repairAortic valveMitral regurgitationIn patientTranscatheter aorticDiastoleMedicineEjection fraction
345Publications
36H-index
4,247Citations
Publications 341
Newest
#1Bassim El-Sabawi (Mayo Clinic)H-Index: 6
#2Mayra Guerrero (Mayo Clinic)H-Index: 24
Last. Charanjit S. Rihal (Mayo Clinic)H-Index: 96
view all 6 authors...
OBJECTIVES To determine the incidence, characteristics, and outcomes of patients with hemolysis after transcatheter mitral valve replacement (TMVR). BACKGROUND Hemolysis is an increasingly recognized complication of TMVR. Clinical outcomes and optimal management for patients with hemolysis after TMVR are unclear. METHODS Patients that underwent mitral valve-in-valve (MViV), valve-in-ring (MViR), and valve-in-mitral annular calcification (ViMAC) at a single center were retrospectively assessed. R...
Source
#1Songnan Wen (Mayo Clinic)
#2Cristina Pislaru (Mayo Clinic)H-Index: 17
Last. Samuel J. Asirvatham (Mayo Clinic)H-Index: 57
view all 8 authors...
Purpose Both warfarin and non-vitamin K antagonist oral anticoagulants (NOACs) have pleiotropic effects including anti-inflammatory and anti-fibrotic properties. This study aims to explore whether arrhythmia recurrence after AF ablation is influenced by the choice of oral anticoagulant. Methods We retrospectively studied all patients who underwent primary AF ablation between 2011 and 2017 and divided them into two groups according to the anticoagulant used: Warfarin vs. NOACs. The primary endpoi...
Source
Source
Source
Source
Source
Source
#1Jwan A Naser (Mayo Clinic)H-Index: 1
#2Arman Arghami (Mayo Clinic)H-Index: 5
Last. Sorin V. Pislaru (Mayo Clinic)H-Index: 36
view all 4 authors...
Source
#1Jwan A Naser (Mayo Clinic)H-Index: 1
#2Ioana Petrescu (Mayo Clinic)H-Index: 4
Last. Sorin V. Pislaru (Mayo Clinic)H-Index: 36
view all 10 authors...
Objective Bioprosthetic valve thrombosis (BPVT) is increasingly recognised as a major cause of prosthetic dysfunction in the first years postimplantation. How early abnormal gradients can be detected prior to diagnosis and how fast they normalise with anticoagulant therapy is unknown. We set forth to (1) evaluate patterns of increase in gradients prior to BPVT diagnosis and (2) characterise time-course of response to anticoagulation. Methods Patients treated with warfarin for BPVT (1999–2019) wi...
Source
Source